Contents

Search

alisertib (Aurora A kinase inhibitor MLN8237)

Indications: - investigative agent for treatment of - colorectal adenocarcinoma [7], - breast cancer, - small cell lung cancer - non-small cell lung cancer - gastro-esophageal adenocarcinoma - head & neck squamous carcinoma [6] - B-cell lymphoma & T-cell lymphoma [4,5] Mechanism of action: - Aurora A kinase inhibitor

General

small inhibitory antineoplastic agent (ib drug) protein kinase inhibitor

Database Correlations

PUBCHEM correlations

References

  1. Wikipedia: Alisertib https://en.wikipedia.org/wiki/Alisertib
  2. PubChem: 24771867
  3. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alisertib
  4. Kelly et al. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma Clin Cancer Res; 24(24) December 15, 2018 PMID: 30082475 http://clincancerres.aacrjournals.org/content/24/24/6150.full-text.pdf
  5. Friedberg, JW et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. Journal of Clinical Oncology. 32 (1): 44-50. PMID: 24043741
  6. Melichar B, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncoloby VOLUME 16, ISSUE 4, P395-405, APRIL 01, 2015 https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)70051-3.pdf
  7. https://www.centerwatch.com/clinical-trials/listings/196186/mucinous-adenocarcinoma-of-the-colon-irinotecan-alisertib-treating-patients/?